AZN

Astrazeneca plc

Feb 05 • 03:57PM ET

187.60

+0.15 0.08 %

Healthcare • Drug Manufacturers - General • United Kingdom • NYSE

Held by: PVAL AVDE DIHP DFIC PPH FVD DFAX PLDR APIE RODM

Index	-	P/E	31.15	EPS (ttm)	6.02	Insider Own	4.81%	Shs Outstand	1.55B	Perf Week	2.42%
Market Cap	290.86B	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.48B	Perf Month	-1.52%
Enterprise Value	315.39B	PEG	-	EPS next Q	-	Inst Own	53.80%	Short Float	-	Perf Quarter	14.56%
Income	9.40B	P/S	5.00	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	32.09%
Sales	58.13B	P/B	6.34	EPS next Y	-	ROA	8.57%	Short Interest	-	Perf YTD	6.89%
Book/sh	29.60	P/C	35.55	EPS next 5Y	-	ROE	21.70%	52W High	195.00 -3.80%	Perf Year	42.12%
Cash/sh	5.28	P/FCF	22.21	EPS past 3/5Y	285.86% 34.63%	ROIC	13.06%	52W Low	122.26 53.44%	Perf 3Y	55.68%
Dividend Est.	-	EV/EBITDA	16.37	Sales past 3/5Y	12.64% 17.27%	Gross Margin	73.23%	Volatility	3.05% 2.70%	Perf 5Y	87.90%
Dividend TTM	3.16 (1.68%)	EV/Sales	5.43	EPS Y/Y TTM	44.64%	Oper. Margin	21.86%	ATR (14)	6.64	Perf 10Y	325.39%
Dividend Ex-Date	Aug 08, 2025	Quick Ratio	0.69	Sales Y/Y TTM	13.52%	Profit Margin	16.17%	RSI (14)	53.41	Recom	-
Dividend Gr. 3/5Y	2.80% 2.47%	Current Ratio	0.88	EPS Q/Q	77.36%	SMA20	1.08%	Beta	0.39	Target Price	-
Payout	69.15%	Debt/Eq	0.71	Sales Q/Q	11.99%	SMA50	2.15%	Rel Volume	17.83	Prev Close	187.45
Employees	94300	LT Debt/Eq	0.57	Earnings	Feb 10 BMO	SMA200	18.28%	Avg Volume	173.22K	Price	187.60
IPO	Oct 17, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.80% 2.79%	Trades		Volume	3,066,028	Change	0.08%

Today 09:15AM	Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:48AM	Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption? (Zacks)
08:31AM	AstraZeneca to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-04-26 12:30PM	Shell chief exec to become one of FTSEs best paid bosses (The Telegraph)
12:29PM	Health Care Roundup: Market Talk (The Wall Street Journal)
10:19AM	Loading…
10:19AM	AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus (Zacks)
10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
Feb-03-26 06:15PM	Why Astrazeneca (AZN) Dipped More Than Broader Market Today (Zacks)
02:30PM	AstraZeneca Stock Soared 103% Monday, Holding At High Level. Gets Rating Upgrade. (Investor's Business Daily)
11:48AM	FDA Rejects AstraZeneca's Saphnelo Injection, Shares Drop 1.9% (GuruFocus.com)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
11:34AM	Jim Cramer Says "I Like AstraZeneca Very Much" (Insider Monkey)
11:02AM	Walmart hits $1 trillion market cap, joins tech giants (Investing.com)
07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy (Business Wire)
06:55AM	AstraZeneca Responds With Data After FDA Delays Lupus Drug Shot (Benzinga)
05:11AM	Loading…
05:11AM	FDA launches PreCheck program; AstraZeneca, Acadia drugs set back (BioPharma Dive)
04:34AM	AstraZeneca PLC (NASDAQ:AZN) Announces Strategic Collaboration Agreement With CSPC Pharmaceuticals (Insider Monkey)
02:42AM	AstraZenecas Initial Application for Lupus Injection Turned Down by FDA (The Wall Street Journal)
Feb-02-26 02:15PM	Should You Buy the Dip in IonQ Stock? (Barchart)
02:04PM	US and India reach trade deal, Astrazeneca shares move to NYSE (Yahoo Finance Video)
12:29PM	AstraZeneca Moves to NYSE as $50 Billion US Investment Plan Takes Focus (GuruFocus.com)
11:00AM	AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC (Zacks)
10:01AM	AstraZeneca Shares Start Trading in US After Listing Upgrade (Bloomberg)
07:00AM	AstraZeneca begins trading on the New York Stock Exchange (Business Wire)
Jan-30-26 12:28PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:11AM	Block quotes in PNR test (Test Provider for Finance)

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc

Upgrade your FINVIZ experience